Cervicovaginal fluid acetate: a metabolite marker of preterm birth in symptomatic pregnant women by Amabebe, E. et al.
October 2016 | Volume 3 | Article 481
Original research
published: 10 October 2016
doi: 10.3389/fmed.2016.00048
Frontiers in Medicine | www.frontiersin.org
Edited by: 
Sinuhe Hahn, 
University of Basel, Switzerland
Reviewed by: 
Peter Sedlmayr, 
Medical University of Graz, Austria 
Tanja Premru-Sršen, 
University Medical Center 
Ljubljana, Slovenia
*Correspondence:
Dilly O. C. Anumba 
d.o.c.anumba@sheffield.ac.uk
Specialty section: 
This article was submitted to 
Obstetrics and Gynecology, 
a section of the journal 
Frontiers in Medicine
Received: 18 August 2016
Accepted: 28 September 2016
Published: 10 October 2016
Citation: 
Amabebe E, Reynolds S, Stern V, 
Stafford G, Paley M and 
Anumba DOC (2016) Cervicovaginal 
Fluid Acetate: A Metabolite Marker of 
Preterm Birth in Symptomatic 
Pregnant Women. 
Front. Med. 3:48. 
doi: 10.3389/fmed.2016.00048
cervicovaginal Fluid acetate: 
a Metabolite Marker of Preterm Birth 
in symptomatic Pregnant Women
Emmanuel Amabebe1, Steven Reynolds2, Victoria Stern1, Graham Stafford3, Martyn Paley2 
and Dilly O. C. Anumba1*
1 Academic Unit of Reproductive and Developmental Medicine, University of Sheffield, Sheffield, UK, 2 Academic Unit of Radiology, 
University of Sheffield, Sheffield, UK, 3 Integrated BioSciences, School of Clinical Dentistry, University of Sheffield, Sheffield, UK
Changes in vaginal microbiota that is associated with preterm birth (PTB) leave spe-
cific metabolite fingerprints that can be detected in the cervicovaginal fluid (CVF) using 
metabolomics techniques. In this study, we characterize and validate the CVF metab-
olite profile of pregnant women presenting with symptoms of threatened preterm labor 
(PTL) by both 1H-nuclear magnetic resonance spectroscopy (NMR) and enzyme-based 
spectrophotometry. We also determine their predictive capacity for PTB, singly, and in 
combination, with current clinical screening tools – cervicovaginal fetal fibronectin (FFN) 
and ultrasound cervical length (CL). CVF was obtained by high-vaginal swabs from 82 
pregnant women with intact fetal membranes presenting between 24 and 36 weeks 
gestation with symptoms of threatened, but not established, PTL. Dissolved CVF sam-
ples were scanned with a 400 MHz NMR spectrometer. Acetate and other metabolites 
were identified in the NMR spectrum, integrated for peak area, and normalized to the 
total spectrum integral. To confirm and validate our observations, acetate concentrations 
(AceConc) were also determined from a randomly-selected subset of the same samples 
(n = 57), by spectrophotometric absorption of NADH using an acetic acid assay kit. CVF 
FFN level, transvaginal ultrasound CL, and vaginal pH were also ascertained. Acetate 
normalized integral and AceConc were significantly higher in the women who delivered 
preterm compared to their term counterparts (P = 0.002 and P = 0.006, respectively). 
The 1H-NMR-derived acetate integrals were strongly correlated with the AceConc esti-
mated by spectrophotometry (r = 0.69; P < 0.0001). Both methods were equally predic-
tive of PTB <37 weeks (acetate integral: AUC = 0.75, 95% CI = 0.60–0.91; AceConc: 
AUC = 0.74, 95% CI = 0.57–0.90, optimal predictive cutoff of >0.53 g/l), and of delivery 
within 2 weeks of the index assessment (acetate integral: AUC = 0.77, 95% CI = 0.58–
0.96; AceConc: AUC = 0.68, 95% CI = 0.5–0.9). The predictive accuracy of CVF acetate 
was similar to CL and FFN. The combination of CVF acetate, FFN, and ultrasound CL in 
a binary logistic regression model improved the prediction of PTB compared to the three 
markers individually, but CVF acetate offered no predictive improvement over ultrasound 
CL combined with CVF FFN. Elevated CVF acetate in women with symptoms of PTL 
appears predictive of preterm delivery, as well as delivery within 2 weeks of presentation. 
An assay of acetate in CVF may prove of clinical utility for predicting PTB.
Keywords: cervicovaginal fluid, microbiota, metabolite, acetate, preterm birth
2Amabebe et al. Acetate as a Marker of Preterm Birth
Frontiers in Medicine | www.frontiersin.org October 2016 | Volume 3 | Article 48
inTrODUcTiOn
Approximately 15 million babies are born prematurely annu-
ally. Preterm birth (PTB, birth before 37 weeks of gestation), is 
a global problem costing health care resources in excess of $26 
billion in the USA and £3 billion in the UK annually. It is the 
commonest cause of infant morbidity and mortality worldwide. 
About 35% of the world’s 3.1 million neonatal deaths annually are 
due to complications of PTB. Many surviving preterm babies face 
a lifetime of disability including cerebral palsy, learning, visual, 
and respiratory disorders amongst others (1–3). Preventing pre-
maturity remains limited by poor prediction, and current tests to 
identify women at risk are inadequate.
Although the etiology of PTB is multifactorial, infection 
and inflammation are associated with most spontaneous pre-
term deliveries (3). However, the etiological mechanisms and 
pathogenesis of these observations are unclear. Changes in the 
vaginal microecology of commensal and potentially pathogenic 
organisms such as bacterial vaginosis (BV) – a polymicrobial 
vaginal infection common in reproductive-aged women – may 
influence the initiation of PTB (3). BV is characterized by a shift 
(dysbiosis) from the healthy Lactobacillus-dominated vaginal 
microflora to an abnormal microbial environment dominated by 
mixed anaerobes e.g., Gardnerella, Fusobacterium, Bacteroides, 
Prevotella, Mobiluncus, Mycoplasmas, etc. These anaerobes 
synthesize metabolic acids such as acetate, butyrate, propionate, 
and succinate, thereby increasing the vaginal pH and inhibit-
ing chemotaxis of immunocompetent cells (4–6). This, in turn, 
enhances the proliferation of these infectious organisms, leading 
to ascending intrauterine infection and the establishment of an 
NF-κB-coordinated inflammatory state (6) that recruits pro-
inflammatory cytokines (e.g., IL-1β, IL-4, IL-6, IL-17, TNF-α, 
and INF-γ) and chemokines (e.g., IL-8 and RANTES), stimulat-
ing the production of matrix metalloproteinases (MMPs) and 
arachidonic acid metabolites such as prostaglandins (PGs) and 
hydroxyeicosatetraenoic acids (HETE). The MMPs degrade and 
digest the cervical extracellular matrix and fetal membranes, 
while the arachidonic acid metabolites modulate myometrial 
contractility leading to cervical remodeling, preterm labor (PTL), 
premature membrane rupture, and ultimately PTB (3, 7–10).
Determination of vaginal microbiota metabolite signatures 
has provided clinically useful insight into the pathophysiology 
of ascending genital tract infection and subsequent reproductive 
outcome (11–13). Metabolic acids (e.g., acetate and succinate) 
produced in large amounts by female genital microbiota (domi-
nated by mixed anaerobic bacteria and deficient in the protective 
lactic acid-producing Lactobacillus species) have been shown 
to exhibit deleterious immunomodulatory functions (6). These 
include increasing the pH of the vaginal ecosystem, inducing 
the production of pro-inflammatory cytokines, and paralyzing 
the chemotaxis of neutrophils, monocytes, and other immuno-
competent cells (4, 5, 14). These encourage luxuriant growth and 
proliferation of potentially pathogenic bacteria, ascending genital 
infection, microbial invasion of the amniotic cavity, and inflam-
mation of the fetal membranes and other gestational tissues. The 
cumulative effect of this sequence of events during gestation 
is the release of PGs and MMPs, and consequently cervical 
remodeling, myometrial contraction, preterm premature rupture 
of membranes, PTL, and preterm delivery (3, 8, 10, 15–17).
Interestingly, the changes in the vaginal microbiota also leave 
specific signature metabolite fingerprints that can be detected in 
the cervicovaginal fluid (CVF) using metabolomics techniques 
such as 1H-nuclear magnetic resonance spectroscopy (NMR) 
(11, 13). In addition to enhancing our understanding of the 
pathogenesis of inflammation-induced PTB, it is plausible 
that CVF metabolite profiling can enable the development of 
clinical predictive tests for identifying women at risk of PTB. 
Besides, some of these metabolites have been useful in the 
diagnosis of BV (12), and more recently, we have demonstrated 
the predictive potential of CVF acetate (derived by 1H-NMR) for 
PTB especially in symptomatic pregnant women (18). Hence, 
in this study employing commercial spectrophotometric assay 
techniques with potential for clinical applicability, we validated 
metabolite profiles previously determined by 1H-NMR spectros-
copy in CVF obtained from a large cohort of pregnant women 
presenting with symptoms suggestive of threatened PTL and 
determined their prognostic capacity for PTB singly and in 
conjunction with widely employed clinical assessment methods 
such as quantitative fetal fibronectin (FFN) and ultrasound 
cervical length (CL). We hypothesized that, compared to their 
term-delivered counterparts; symptomatic pregnant women 
who ultimately delivered prematurely would have significantly 
different CVF metabolite profiles with predictive accuracies 
comparable to current clinical tests such as cervicovaginal FFN 
and ultrasound-derived CL.
MaTerials anD MeThODs
study cohort and sampling
Cervicovaginal fluid was obtained by high-vaginal swabs 
(Deltalab Eurotubo 300263, Fisher Scientific, UK) from pregnant 
women presenting to the Triage Delivery Suites of the Jessop Wing 
Hospital, Sheffield, UK, with symptoms suggestive of threatened, 
but not established, PTL (i.e., regular uterine contractions at least 
once every 10 min and cervical dilatation <3 cm), between 24 
and 36  weeks gestation (n =  82). Women with multiple gesta-
tion, symptoms or signs of genitourinary infection, and history 
of abnormal cervical cytology in the last 3 years, ruptured fetal 
membranes, and prior vaginal examinations at presentation 
were excluded from the study. Study participants were recruited 
between January 2014 and September 2015 and closely monitored 
until delivery outcome was ascertained.
Vaginal swabs were obtained from participants prior to any 
vaginal examination or clinical treatment intervention such 
as therapy with antibiotics, steroids, tocolytics, or any vaginal 
pessary. The obtained CVF samples were instantly processed 
or stored at −20°C in preparation for metabolite analyses. At 
presentation, clinical research staff also ascertained CVF FFN, 
ultrasound CL, and vaginal pH. The clinical course and delivery 
outcomes of participants were subsequently ascertained.
These studies were approved by the Yorkshire & Humber 
(Sheffield) Committee of the UK National Research Ethics 
Service (REC Number 13/YH/0167).
FigUre 1 | 1h-nMr spectrum of identified metabolites in cervicovaginal fluid (cVF) and sterile swab at 400 Mhz and 294 K. Due to the presence of 
other additional metabolite peaks at the δ = 3.2 ppm and 3.9 ppm region, the glucose signal at δ = 5.2 ppm was integrated and used in subsequent analysis. 
BCAA, Branched chain amino acids (leucine, isoleucine, and valine) (δ = 0.9–1.2 ppm), ppm, parts per million.
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1h-nMr spectroscopy
Cervicovaginal fluid samples were prepared and analyzed by 
1H-NMR as previously described (18). Dacron swab saturated 
with CVF obtained from the posterior fornix of the vagina 
was immediately returned to the sterile transport tube, labeled 
correctly, and stored briefly at −20°C pending extraction into 
solution. A physiological extraction solution of 600 μl Phosphate 
Buffered Saline at pH 7.4 was added to the cut end of the swab 
saturated with CVF sample in a clean 1.5 ml microfuge tube and 
vortexed for 5  min. The swab was safely discarded after CVF 
had been washed off into solution. Following centrifugation 
(13,000 rpm × 3 min), the supernatant was separated and care-
fully aspirated into a different clean 1.5 ml microfuge tube and 
stored at −80°C ready for analysis. Four hundred microliters of 
each NMR sample comprising of 380 μl of CVF in solution and 
20 μl of deuterium oxide (D2O) was transferred into a 5 mm NMR 
sample tube (Norell, Marion, NC, USA), ready for scanning.
1H-NMR spectra of CVF samples were acquired at approxi-
mately 294  K with a 9.4T (400  MHz) Bruker Avance III MR 
spectrometer (Bruker BioSpin GmbH, Karlsruhe, Germany), 
with 5 mm broadband observe probe using a Watergate water 
suppression pulse sequence (number of scans, NS = 256, relaxa-
tion time, D1 = 5 s, acquisition time, AQ = 1 s, sweep width, 
SW = 20.6 ppm, time domain, TD = 16446). 1H-NMR spectra 
phase and baseline correction as well as data processing was 
performed using the Bruker TOPSPIN 2.1.6 software.
In order to confirm the structure of the identified metabolites 
and assign them to the 1H-NMR spectral peaks (Figure  1), 
the following 2-D NMR spectra were acquired 1H-13C presat- 
heteronuclear single quantum correlation spectroscopy (HSQC) – 
NS = 1024, D1 = 1 s, AQ = 0.078 × 0.006 s, SW = 10.0 × 150 ppm, 
TD =  624  ×  180; 1H-13C presat-heteronuclear multiple bond 
correlation spectroscopy (HMBC) – NS  =  1024, D1  =  1  s, 
AQ = 0.128 × 0.005 s, SW = 10.0 × 230 ppm, TD = 1024 × 200; 
1H-1H watergate-double quantum filtered correlation spectros-
copy (DQFCOSY) – NS = 256, D1 = 0.5 s, AQ = 0.832 × 0.022 s, 
SW = 9.0 × 9.0 ppm, TD = 6000 × 160; and 1H-1H presat-clean 
total correlation spectroscopy (TOCSY) – NS = 16, D1 = 1.5 s, 
AQ = 0.284 × 0.071 s, SW = 9.0 × 9.0 ppm, TD = 2048 × 512. 
A  representative 2-D 1H-13C HSQC spectrum is shown in 
Figure S1 in Supplementary Material. All spectral peaks were ref-
erenced to the 1H lactate signal at δ = 1.30 ppm. The metabolite 
peak intensities were then assigned by matching their chemical 
shifts and multiplicity with previous publications (13, 19), SDBS 
Spectral Database for Organic Compounds (http://sdbs.db.aist.
go.jp/sdbs/cgi-bin/cre_index.cgi), and Chenomx NMR Suite 
software package (Chenomx Inc., CA, USA, version 7.7). With 
the same experimental procedures, a sterile (unused) polysty-
rene Dacron swab was prepared and analyzed as a background 
control signal.
The identified 1H-NMR metabolite signals were integrated for 
peak area (which is proportional to metabolite concentration) 
TaBle 1 | Maternal clinical and demographic characteristics.
characteristics symptomatic pregnant women 24–36 weeks gestation
Preterm (N = 15) Term (N = 67)
Age (years) 31.1 ± 2.0b (22–48, n = 15) 26.6 ± 0.7 (16–44, n = 67)
BMI (kg m−2) 28.9 + 1.9a (20.1–42.5, n = 11) 25.1 ± 0.6a (17.4–41.6, 
n = 56)
Previous history 
of PTB (n)
5 10
Cigarette 
smokers, n (%)
1(7) 10(15)
Cervical length 
(mm)
21.1 ± 4.8a (7–45, n = 8) 30.8 ± 1.6ba (11–54, n = 37)
Fetal fibronectin 
conc. (ng/ml)
188 ± 85ba (5–501, n = 6) 15.2 ± 3a (1–74, n = 37)
Gestational age 
at presentation 
(days)
206 ± 5.4 (177–237, n = 15) 213 ± 3.1 (139–254, n = 67)
Gestational age 
at delivery (days)
221 ± 5.7 (187–257, n = 15) 275 ± 1.1 (260–295, n = 61)
Vagina pH 4.4 ± 0.3a (3.6–6.1, n = 7) 4.2 ± 0.1a (3.6–6.1, n = 36)
Prevalence of 
PTB, %
18.3
Data are presented as mean ± SEM (range, n); BMI, body mass index; PTB, preterm 
birth; N, total number of term- or preterm-delivered women; n, actual number of 
women for each clinical parameter obtained.
aReduced study population (n) due to absence of participants’ consent and/or data.
bDifferences between preterm and term-delivered women, P < 0.05.
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and normalized by dividing each integral by the total spectrum 
integral (δ = 0.0–10.0 ppm, excluding the residual water signal 
δ = 4.7–5.0 ppm) to provide a normalized integral (N.I.). This 
accounted for any differences in CVF concentration or variation 
in swab sampling.
cVF acetate concentration Measurement
To validate and confirm the data from NMR-derived acetate 
normalized integrals, predictive accuracy of CVF acetate for PTB 
and explore potential clinical translation, we determined absolute 
acetate concentration from a randomly-selected subset of CVF 
samples (n = 57) from the total cohort of participants, by spec-
trophotometric absorption of NADH using an assay kit for acetic 
acid (ADP-Glucokinase format, K-ACETGK 08/14, Megazyme, 
IE). The reaction is a positive reaction indicated by the increase in 
absorbance as demonstrated by the calibration curve (R2 = 0.975, 
detection limit: 1.8 g/l), with its lowest sensitivity limit ~0.1 g/l 
(R2 = 0.9997) (Figure S2 in Supplementary Material). The acetic 
acid GK assay kit is an endpoint type assay specific for acetate. 
All reagents were prepared, mixed, and stored according to the 
manufacturer’s instruction. A single reaction mixture contain-
ing 3 μl CVF sample in PBS, 200 μl of reagent 1 (distilled water, 
buffer, and AK/PTA/ADP-GK/G6P-DH), and 20 μl of reagent 
2 (NAD  +  /ATP/D-glucose/CoA/PVP), was assayed for each 
sample. The reaction time was ~ 5 min at 37°C after which the 
absorbance of the end product NADH was read at 340 nm. All 
assays were performed using optical grade 96-well plates on a 
computer-controlled Infinite M200 microplate reader (TECAN, 
Chapel Hill) {wavelength range =  230–1000  nm; accuracy: 0–2 
OD: ≤± [1% + 10 mOD; 2–3 OD: ≤±2.5%; Precision <0.2% at 
260  nm; Linearity: R2 =  0.999 (0–2 OD)]} (see Supplementary 
Material for more details).
cVF Fetal Fibronectin, Ultrasound  
cl, and Vaginal ph
Quantitative CVF FFN levels were determined using the 10Q 
Rapid FFN analyser (Hologic, MA, USA), vaginal pH using nar-
row range universal indicator paper (pH-Fix, Machery-Nagel, 
DE, USA), and CL by transvaginal ultrasonography.
Data analysis
All statistical analyses, including receiver operating characteris-
tics (ROC) curve determination were performed using MATLAB 
(Mathworks, Natick, MA, USA). The Wilcoxon rank-sum test 
was performed to compare differences in metabolite N.I. and 
concentration between term and preterm-delivered women 
within the group. Post hoc adjustment for multiple comparisons 
was undertaken by the Bonferroni test. Values are presented as 
mean ± SEM (except where otherwise stated). The relationships 
between maternal clinical data, acetate concentration, and 1H-
NMR metabolite N.I. were determined by Pearson’s correlation 
coefficients and P values <0.05 were considered statistically sig-
nificant. The predictive capacity of the CVF metabolites for PTB 
was determined by ROC curves for the following comparisons:
• Preterm (<37 weeks) vs. term births,
• Preterm birth <32 vs. >32 weeks gestation,
• <2 vs. >2 weeks from presentation to delivery.
A cutoff value of acetate concentration for predicting PTB 
<37 weeks gestation was also calculated from the ROC curve. 
The combined predictive accuracy of FFN, ultrasound CL, and 
CVF acetate was estimated by binary logistic regression and 
combined area under the ROC curve analysis (MedCalc Software 
bvba, BE, USA).
resUlTs
Participants’ clinical Details and 
Pregnancy Outcome
Participants’ clinical characteristics and delivery outcomes 
are summarized in Table 1. Also, 18.3% (15/82) of the women 
delivered preterm (<37  weeks), with mean duration of time 
between presentation and delivery of 15.7 ± 3.5 (preterm) and 
60.3  ±  3.2  days (term). Of the 15 PTBs recorded, 8 women 
(9.8% of the total study population) delivered before 32  weeks 
of gestation.
1h-nMr Derived normalized integrals
A representative 1H-NMR spectrum of identified metabolites is 
shown in Figure 1.
Comparison of CVF metabolite N.I.s derived by 1H-NMR 
showed significantly higher (0.03 ±  0.01 vs. 0.01 ±  0.003 a.u.; 
P = 0.002) acetate N.I. in women who delivered preterm com-
pared to their term counterparts. There was about threefold 
increase in acetate N.I. in women who ultimately delivered 
preterm (Figure 2A).
FigUre 2 | comparison of cVF (a) acetate normalized integral measured by 1h-nMr (B) acetate concentration measured by spectrophotometry 
between preterm and term women. Error bars = SEM; a.u., arbitrary unit.
TaBle 2 | Predictive accuracy of cVF acetate 1h-nMr normalized integral and concentration for preterm birth.
aUc 95% ci sens (%) spec (%) PPV (%) nPV (%) lr+ lr− P value
Delivery <37 weeks gestation
Acetate N.I. 0.75 0.60–0.91 60 85 47 91 4.0 0.2 0.001
AceConc 0.74 0.57–0.90 71 71 36 92 2.5 0.4 0.002
Delivery <32 weeks gestation
Acetate N.I. 0.73 0.53–0.94 88 59 21 97 2.1 0.5 0.01
AceConc 0.63 0.40–0.87 72 63 19 95 2.0 0.5 0.13
Delivery within 2 weeks of assay
Acetate N.I. 0.77 0.58–0.96 100 49 21 100 2.0 0.5 0.003
AceConc 0.68 0.47–0.89 67 79 29 95 3.1 0.3 0.045
Acetate N.I., 1H-NMR acetate normalized integral; AceConc, acetate concentration measured by spectrophotometric technique; AUC, area under the ROC curve; CI, 95% 
confidence interval; Sens, sensitivity; Spec, specificity; PPV, positive predictive value; NPV, negative predictive value; LR+, positive likelihood ratio; LR−, negative likelihood ratio;  
P, significance level.
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Additionally, ROC curve analysis showed that acetate N.I. 
was predictive of PTB <37 weeks (area under the ROC curve, 
AUC =  0.75, 95% CI =  0.60–0.91), <32  weeks (AUC =  0.73, 
95% CI = 0.53–0.94), and delivery within 2 weeks of the index 
assessment (AUC =  0.77, 95% CI =  0.58–0.96) (Table  2 and 
Figure 3).
Normalized integrals of succinate, formate, lactate, glucose, 
glutamine/glutamate, alanine, and branched chain amino acids 
did not differ between term- and preterm-delivered women.
acetate concentration Measured by 
spectrophotometry
Similar to our observation with acetate N.I., AceConc meas-
ured by the spectrophotometric technique was significantly 
higher in the preterm-delivered vs. term-delivered women 
(0.63 ± 0.04 vs. 0.54 ± 0.01 g/l; P = 0.006) (Figure 2B), and 
correlated strongly with the 1H-NMR acetate N.I. (r =  0.69, 
P < 0.00001) (Figure 4).
Furthermore, acetate concentration measured by the spec-
trophotometric technique was predictive of PTB <37  weeks 
(AUC = 0.74, 95% CI = 0.57–0.90) and delivery within 2 weeks 
of the index assessment (AUC = 0.68, 95% CI = 0.47–0.89), with 
an optimal cutoff value of >0.53 g/l. However, its predictive per-
formance for PTB <32 weeks did not attain statistical significant 
in this limited sample (Table 2; Figure 3).
cVF FFn, Ultrasound cl, and Vaginal ph
The women destined to deliver preterm had significantly shorter 
mean CL (21.1  ±  4.8 vs. 30.8  ±  1.6  mm) and greater than 
12-fold higher FFN concentration (188 ± 85 vs. 15.2 ± 3 ng/ml) 
compared to their term counterparts (Table 1 and Figure S3 in 
Supplementary Material). Both FFN (r =   −0.7, P <  0.00001) 
FigUre 3 | Predictive accuracy of cVF acetate for preterm birth (a) before 37 weeks and (B) within 2 weeks of index assessment in pregnant women 
with symptoms of preterm labor. CVF acetate is measured by 1H-NMR (acetate normalized integral) and spectrophotometry (acetate concentration).
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and CL (r =  0.4, P =  0.01) correlated with gestational age at 
delivery (GAAD) (an indication of term or PTB) (Figure S4 in 
Supplementary Material).
Also, analysis of the area under the ROC curve showed 
FFN, and ultrasound CL were predictive of PTB <37  weeks 
(Table 3).
Vaginal pH did not differ between term- and preterm-
delivered women (Table 1), but it correlated with acetate (r = 0.4, 
P = 0.01) and lactate N.I.’s (r =  −0.6, P < 0.00001) (Figure S5 in 
Supplementary Material).
combined Predictive Performance of 
cVF acetate, FFn, and Ultrasound cl
Apart from the observation of comparable predictive capacities 
between CVF acetate, FFN, and ultrasound CL (Table 3), combin-
ing CVF acetate estimated by 1H-NMR and spectrophotometry 
with these widely used clinical assessment markers improved the 
prediction of PTB – the inclusion of either CVF acetate N.I. or 
acetate concentration with FFN and ultrasound CL in a binary 
logistic regression model improved prediction of PTB before 
37  weeks gestation (AUC  =  0.86, sensitivity 83%, specificity 
FigUre 4 | cervicovaginal fluid acetate of symptomatic pregnant 
women estimated by 1h-nMr and spectrophotometry. a.u., arbitrary unit.
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89%, LR+ 7.3, and LR− 0.2 for acetate N.I. and AUC =  0.80, 
sensitivity 80%, specificity 84%, LR+ 5.0 and LR− 0.2 for acetate 
concentration) than each of the three markers considered singly 
(Figures  5A,B). However, the combination of FFN and ultra-
sound CL alone indicated comparable predictive power to all 
three markers combined together (AUC = 0.84) (Table 3).
DiscUssiOn
We have employed 1H-NMR spectroscopy to characterize 
the CVF metabolite profiles of a cohort of pregnant women 
presenting with symptoms suggestive of threatened PTL at 
mid-gestation and determined their prognostic accuracy for 
PTB. Consistent with our previous report (18), we confirmed 
that CVF acetate appears predictive of PTB in this cohort. 
Furthermore, we have now validated this observation in this 
report employing commercially available enzyme-based spec-
trophotometric assay kits for acetic acid. We observed that CVF 
acetate predicted PTB as well as quantitative FFN and ultra-
sound CL, and that when combined with these determinations, 
predictive accuracy for preterm delivery before 37 weeks gesta-
tion improved moderately. To our knowledge, this comparative 
analysis is the first of its kind.
Of the metabolites identified in the 1H-NMR spectra of CVF 
samples of women presenting with features of PTL, only acetate 
levels were associated with preterm delivery. The women destined 
to deliver prematurely had a twofold higher acetate N.I. compared 
to those who delivered at term. Acetate N.I. was also prognostic 
of PTB before 37 and 32 weeks of gestation, as well as of delivery 
within 2  weeks of the index assessment. Measurement of CVF 
acetate levels by 1H-NMR, which is a marker of altered vaginal 
microbiota (6), is associated with imminent PTB.
However, acetate N.I. determination by 1H-NMR assess-
ment does not lend itself to clinical use as an assay technique. 
We therefore validated 1H-NMR data by determining absolute 
concentrations of acetate in CVF by employing a commercial 
spectrophotometric assay technique from a randomly selected 
subset of the same symptomatic pregnant women. We deter-
mined that acetate concentration derived by spectrophotometry 
correlated strongly with 1H-NMR-derived acetate N.I. being 
significantly higher in the women who ultimately delivered 
preterm. Additionally, acetate concentration was predictive 
FigUre 5 | aUrOcs depicting combined PTB predictive performance of fetal fibronectin (FFn), cervical length and cVF acetate estimated by 
1h-nMr (a), and spectrophotometry (B).
TaBle 3 | individual and combined predictive values of cVF acetate, fetal 
fibronectin, and cervical length for preterm birth.
Test aUrOc (95% ci)
Acetate N.I. 0.75 (0.60–91)
AceConc 0.74 (0.57–0.90)
Fetal fibronectin 0.76 (0.53–1.0)
Cervical length 0.73 (0.52–0.94)
Fetal fibronectin + cervical length 0.84 (0.64–1.0)
Fetal fibronectin + cervical length + acetate N.I. 0.86 (0.69–0.95)
Fetal fibronectin + cervical length + AceConc 0.81 (0.62–0.93)
AUROC, area under the ROC curve; Acetate N.I., 1H-NMR acetate normalized integral; 
AceConc, acetate concentration measured by spectrophotometric technique.
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of preterm delivery before 37  weeks gestation and of delivery 
within 2  weeks of the index assessment. However, predictive 
potential for delivery before 32 weeks did not attain statistical 
significance as only eight women in this subset delivered before 
32 weeks gestation.
Conditions characterized by altered vaginal microflora such as 
intermediate flora, aerobic vaginitis, and BV have been implicated 
in infection/inflammation-induced preterm delivery. However, 
BV is the most investigated (3). The earlier the gestational age 
at the onset of PTL and possibly preterm premature rupture of 
membranes leading to PTB, the higher the likelihood of genital 
tract infection and inflammation (e.g., chorioamnionitis) (20). 
More than half of the women who delivered preterm in this 
study and approximately 10% of the entire study population 
delivered very prematurely before 32 weeks. In this category of 
PTBs, subclinical intrauterine infection is most often evident 
(20). As demonstrated in this study, identification of metabolic 
by-products (such as acetate) of pathogenic anaerobic bacteria 
seen in the above conditions could be used as a non-invasive, 
quick, and cost-effective proxy marker for the characterization 
of the prevailing vaginal microbial community and the attendant 
inflammatory state. Understanding these metabolite patterns 
in pregnant women may, therefore, aid understanding of the 
mechanisms of inflammation-induced preterm delivery, as well 
as uncover potential novel therapies.
We also demonstrated a relationship between vaginal pH, 
acetate, and lactate N.I.’s (Figure S5 in Supplementary Material), 
consistent with a potential metabolite signature pattern in women 
destined to deliver preterm. Vaginal pH increases with elevated 
acetate production by anaerobic bacteria (e.g., Gardnerella, 
Prevotella, Bacteroides, Mobilincus, Mycoplasma, etc.) char-
acteristic of BV, while pH decreases with increase in lactate 
predominantly produced by Lactobacillus species characteristic 
of a healthy vaginal microbiota (6). These changes, together 
with increased recruitment of neutrophils, pro-inflammatory 
cytokines, and chemokines (e.g., IL-6 and IL-8), are also strongly 
associated with early third trimester rupture of fetal membranes 
(8, 21) often a precursor of idiopathic spontaneous PTB.
Although quantitative FFN and ultrasound CL are the most 
utilized clinical assessment markers for distinguishing women at 
risk of PTB in asymptomatic and symptomatic cohorts, there use 
is associated with a high rate of false positive results, low sensitiv-
ity, and positive predictive values for PTB (2). Combining both 
tests in midtrimester appears to improve their predictive accuracy 
of PTB (22). Furthermore, an association between genital tract 
infection/inflammation, short cervix, membrane activation and 
disruption, and leakage of FFN has been reported (8, 23). In this 
cohort, CVF acetate appeared as predictive of PTB as CL and FFN 
separately. Considering the limitations of FFN and ultrasound 
CL, we combined them with CVF acetate to determine whether 
the prognostication of PTB could be improved by the multiple 
biomarkers. We have observed that the combination yielded 
improved prediction of PTB.
In summary, we have reported that elevated CVF acetate 
(produced by mixed anaerobes) in women with symptoms of PTL 
appears predictive of preterm delivery, as well as delivery within 
2 weeks of presentation, independently. This is supported by the 
established association of vaginal microbiota dominated by mixed 
anaerobic bacteria with the initiation of inflammation-associated 
PTL and birth. In pregnant women presenting with symptoms 
suggestive of PTL, a clinical assay of acetate in CVF may prove 
of clinical utility for predicting PTB singly and in combination 
with quantitative FFN and ultrasound CL, if our observations are 
confirmed in larger studies. Whether CVF acetate has clinical 
utility for predicting PTB in asymptomatic pregnant women is 
yet to be determined.
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acetic acid spectrophotometric assay
The assay principle is based on the determination of acetate 
concentration by the generation of NADH from NAD+, which is 
then quantified by the increase in absorbance at 340 nm (24). The 
enzymes involved in the four-step reaction and supplied with the 
assay kit include: (1) acetate kinase, (2) phosphotransacetylase, 
(3) ADP-glucokinase (ADP-GK), and (4) glucose-6-phosphate 
dehydrogenase (G6P-DH). Acetate is converted through the 
following reaction, which is positively related to the eventual 
formation of NADH:
 1. Acetic acid + ATP    acetyl-phosphate + ADP
 2. Acetyl-phosphate + CoA  acetyl-
CoA  + Pi
 3. ADP + D-glucose  glucose-6-phos-
phate + AMP
 4. Glucose-6-phosphate + NAD+  
6-phosphogluconate + NADH + H+
The reaction is a positive reaction indicated by the increase 
in absorbance. The acetic acid GK assay kit is an endpoint type 
assay specific for acetate with its lowest sensitivity limit ~0.1 g/l 
(R2  =  0.9997). A calibration curve indicating the linearity of 
K-ACETGK 08/14 was produced by plotting absorbance at 340 nm 
against concentrations of the acetic acid standards (gram per liter) 
(R2 = 0.975, detection limit: 1.8 g/l) (Figure S2 in Supplementary 
Material). Different concentrations (calibrators) of the acetic acid 
standard (1.8 g/l) were made be serial dilution (i.e., 1.8, 1.2, 0.9, 
0.6, 0.45, 0.36, 0.3, 0.225, 0.2, and 0.15 g/l). From the calibration 
curve, concentrations of acetate in the samples were ascertained 
after measurement of their absorbance at 340 nm.
FigUre s1 | 2-D 1h-13c hsQc nMr spectrum of cervicovaginal fluid 
showing confirmed metabolites at 294 K. BCAA, branched chain amino 
acids (leucine, isoleucine, and valine); HSQC, heteronuclear single quantum 
correlation spectroscopy.
FigUre s2 | calibration curve indicating the linearity of K-aceTgK. 
The reactions from which this calibration curve was generated were performed at 
37°C for about 5 min using a TECAN Infinite M200 microplate reader (detection 
limit = 1.8 g/l or 0.03 mol/l).
FigUre s3 | clinical assessment methods for preterm birth (a) 
quantitative fetal fibronectin level and (B) ultrasound cervical length 
in relation to delivery outcomes. Data are presented as mean ± SE. 
*P value < 0.05.
FigUre s4 | association of quantitative fetal fibronectin (FFn) level (a), 
ultrasound cervical length (B), and gestational age at delivery (gaaD).
FigUre s5 | association of vaginal ph and cVF acetate (a) and lactate (B) 
normalized integrals in symptomatic pregnant women. a.u., arbitrary unit.
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